FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and can be used in medicine for preventing and/or treating a subject with a BORIS-expressing tumour. Disclosed are nucleic acid molecules containing one or more nucleic acid sequences encoding the synthetic consensus antigen BORIS. Disclosed are a vector, a vaccine, containing one or more nucleic acid sequences encoding the synthetic consensus antigen BORIS. Disclosed are a method for treating a subject with a BORIS-expressing tumour and a method for vaccinating a subject against one expressing an antigen - Brother of the Regulator of an Imprinted Site (BORIS) of the cancer cell. Disclosed is the synthetic consensus antigen BORIS.
EFFECT: invention proposes a safe and effective vaccine and methods for application thereof for preventing and/or treating cancer and reducing the mortality in subjects suffering from cancer.
17 cl, 16 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER VACCINES TARGETING BORIS AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2759681C1 |
| SURVIVIN-TARGETED ANTI-CANCER VACCINES AND APPLICATIONS THEREOF | 2018 |
|
RU2776949C2 |
| ANTI-CANCER VACCINES TARGETED WITH SURVIVIN AND THEIR APPLICATION | 2018 |
|
RU2751253C1 |
| MUC16-TARGETING ANTICANCER VACCINES AND APPLICATION THEREOF | 2018 |
|
RU2777918C2 |
| ANTI-CANCER VACCINES AIMED AT LEMD1 AND THEIR USE | 2018 |
|
RU2760984C1 |
| ANTI-CANCER VACCINES TARGETING MUC16 AND THEIR USE | 2018 |
|
RU2750689C1 |
| ANTI-CANCER VACCINES TARGETING PRAME AND THEIR APPLICATIONS | 2018 |
|
RU2748903C1 |
| MESOTHELINE-TARGETED CANCER VACCINES AND THEIR APPLICATION | 2018 |
|
RU2751252C1 |
| TOLEROGENIC DNA VACCINE | 2017 |
|
RU2752608C2 |
| CHIMERIC PROTEIN, A SYNTHETIC DNA WHICH CODES SAID PROTEIN, AN EXPRESSION VECTOR, A SYNTHETIC DNA PRODUCING STRAIN AND A METHOD OF PRODUCING PLASMID DNA | 2016 |
|
RU2736472C2 |
